Verrica Pharmaceuticals vs Zhengye Biotechnology Holding
Verrica Pharmaceuticals is the larger business, with $35.6m of revenue in fiscal 2025 against $16.2m for Zhengye Biotechnology Holding (2.2 times as much). Verrica Pharmaceuticals grew faster (370.2% against -37.5%). Verrica Pharmaceuticals kept more of each dollar of sales as profit: a net margin of -50.3% against -60.0%. Verrica Pharmaceuticals carries less debt relative to equity (0.0% against 29.9%).
| Latest fiscal year | Verrica PharmaceuticalsVRCA, 2025 | Zhengye Biotechnology HoldingZYBT, 2025 |
|---|---|---|
| Revenue | $35.6m | $16.2m |
| Revenue growth | 370.2% | -37.5% |
| Net income | −$17.9m | −$9.7m |
| Operating margin | -34.2% | -60.6% |
| Net margin | -50.3% | -60.0% |
| Return on equity | — | -26.0% |
| Free cash flow | −$17.6m | $1.7m |
| Cash | $30.1m | $7.2m |
| Total debt | $0 | $10.7m |
| Debt to equity | 0.0% | 29.9% |
| Dividend per share | — | — |
| Dividend yield | — | 3.5% |
| Share buybacks | — | — |
| Employees | 76 | — |
| Market value | $57.5m | $61.6m |
| Price vs our value range | — | Above our value range |
| Moat score | 8 (Weak) | — |
| Insider trades, 12 months | 12 buys, 0 sales | 0 buys, 0 sales |